Search

Vidarabine

It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the

Guar gum

Tarenflurbil

It is a selective amyloid lowering agent (SALA) that reduces levels of the toxic peptide amyloid beta 42 (Aβ42) in cultured human cells and in animal models. … Tarenflurbil is an investigational drug that was studied in patients with mild Alzheimer's disease.

3,3'-diindolylmethane

Diindolylmethane has been used in trials studying the prevention and treatment of SLE, Prostate Cancer, Cervical Dysplasia, Stage I Prostate Cancer, and Stage II Prostate Cancer, among others.

Emricasan

It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis. … Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA.

NBI-6024

NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.

Avapritinib

[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers.[A189327] Avapritinib shares a similar mechanism with [ripretinib]. … Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464]

Flubendazole

Flubendazole is an anthelmintic that is used to treat worm infection in humans. It is available OTC in Europe.

Telbivudine

Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. … Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects.

Dextropropoxyphene

Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. … Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.